Sarah Cavanaugh's most recent trade in Celldex Therapeutics Inc. was a trade of 78,000 Incentive Stock Option (right to buy) done . Disclosure was reported to the exchange on June 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 78,000 | 78,000 | - | - | Incentive Stock Option (right to buy) | |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 78,000 | 78,000 | - | - | Incentive Stock Option (right to buy) | |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Sale of securities on an exchange or to another person at price $ 33.73 per share. | 30 May 2024 | 20,853 | 1,860 (0%) | 0% | 33.7 | 703,334 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 May 2024 | 10,750 | 0 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.78 per share. | 30 May 2024 | 10,750 | 12,610 (0%) | 0% | 2.8 | 29,885 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.02 per share. | 30 May 2024 | 10,103 | 22,713 (0%) | 0% | 9.0 | 91,094 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 May 2024 | 10,103 | 0 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 75,000 | 75,000 | - | - | Incentive Stock Option (right to buy) | |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Sale of securities on an exchange or to another person at price $ 36.73 per share. | 17 Aug 2022 | 31,312 | 1,284 (0%) | 0% | 36.7 | 1,150,221 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.78 per share. | 17 Aug 2022 | 31,312 | 32,596 (0%) | 0% | 2.8 | 87,047 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2022 | 31,312 | 10,750 | - | - | Incentive Stock Option | |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Sale of securities on an exchange or to another person at price $ 36.38 per share. | 17 Aug 2022 | 1,355 | 1,284 (0%) | 0% | 36.4 | 49,289 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.02 per share. | 17 Aug 2022 | 1,355 | 2,639 (0%) | 0% | 9.0 | 12,217 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2022 | 1,355 | 10,103 | - | - | Incentive Stock Option | |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 73,000 | 73,000 | - | - | Incentive Stock Option (right to buy) | |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP of Corp Affairs & Admin. | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 08 Dec 2021 | 7,323 | 408 (0%) | 0% | 40 | 292,920 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP of Corp Affairs & Admin. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.38 per share. | 08 Dec 2021 | 5,466 | 7,731 (0%) | 0% | 10.4 | 56,737 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP of Corp Affairs & Admin. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2021 | 5,466 | 78,534 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP of Corp Affairs & Admin. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2021 | 1,857 | 11,458 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP of Corp Affairs & Admin. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.02 per share. | 08 Dec 2021 | 1,857 | 2,265 (0%) | 0% | 9.0 | 16,744 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP of Corp Affairs & Admin. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 5,018 | 13,315 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP of Corp Affairs & Admin. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.02 per share. | 01 Nov 2021 | 5,018 | 6,793 (0%) | 0% | 9.0 | 45,245 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP of Corp Affairs & Admin. | Sale of securities on an exchange or to another person at price $ 44.11 per share. | 01 Nov 2021 | 4,302 | 3,429 (0%) | 0% | 44.1 | 189,774 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP of Corp Affairs & Admin. | Sale of securities on an exchange or to another person at price $ 41.62 per share. | 01 Nov 2021 | 2,120 | 408 (0%) | 0% | 41.6 | 88,232 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP of Corp Affairs & Admin. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.78 per share. | 01 Nov 2021 | 938 | 7,731 (0%) | 0% | 2.8 | 2,608 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP of Corp Affairs & Admin. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 938 | 42,062 | - | - | Incentive Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP of Corp Affairs & Admin. | Sale of securities on an exchange or to another person at price $ 43.06 per share. | 01 Nov 2021 | 901 | 2,528 (0%) | 0% | 43.1 | 38,798 | Common Stock |
| Celldex Therapeutics Inc. | Sarah Cavanaugh | SVP of Corp Affairs & Admin. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 56,000 | 56,000 | - | - | Incentive Stock Option (right to buy) |